Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren).
Horisberger K, et al. Among authors: hofheinz rd.
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1487-93. doi: 10.1016/j.ijrobp.2008.10.014. Epub 2009 Jan 7.
Int J Radiat Oncol Biol Phys. 2009.
PMID: 19131187
Clinical Trial.